Compare BCC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCC | ATAI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 7680 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2012 | 2025 |
| Metric | BCC | ATAI |
|---|---|---|
| Price | $76.46 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $99.20 | $15.88 |
| AVG Volume (30 Days) | 422.0K | ★ 10.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $4,995,290,000.00 | $4,089,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | $155.40 | ★ N/A |
| Revenue Growth | 12.71 | ★ 1227.60 |
| 52 Week Low | $65.00 | $3.06 |
| 52 Week High | $91.97 | $7.22 |
| Indicator | BCC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 73.10 |
| Support Level | N/A | $3.56 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.30 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 0.00 | 97.75 |
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.